ProCE Banner Activity

PEACE-1: Overall Survival With Abiraterone With or Without Local Radiotherapy + SoC in de novo Metastatic Castration-Sensitive Prostate Cancer

Slideset Download
Conference Coverage
In this randomized, phase III trial, the addition of abiraterone to ADT plus docetaxel was associated with a significant improvement in rPFS and overall survival in men with de novo metastatic CSPC.

Released: September 27, 2021

Expiration: September 26, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc